partner with us

Developing best in class therapies for rare diseases

Partnering & Investment

NovelMed is currently seeking investments or partners to advance its pipeline of anti-complement antibodies. Our lead candidates are now moving to Phase II clinical trial in Q2 of 2022 for various clinical indications. Our primary indication is PNH but given the unique mechanism of action associated with our antibody platform it has the potential to address a number of additional clinical indications. NovelMed is open to discussions for the license of a subset, or the entire complement platform for one or more indications.

Value  Propositions:        
        - Phase I  clinical trial for NM8074 to complete in Q1, 2022
        - Phase II trial for NM5072 to begin in 2022
        - Advanced  stage antibody platform has the potential to address multiple  indications    
        - Strong intellectual  property with a number of current and pending patents    
        - Undiluted  ownership structure

           We are very interested in licensing our drugs to a partner for their development as novel therapies for rare diseases

A Little About Us

NovelMed Therapeutics is a biotechnology company that conducts cutting-edge research and develops therapeutics for complement-mediated diseases. As a company, we are driven by our commitment to patients and a shared vision to provide innovative new therapies for unmet medical needs. We are focused on developing transformative treatment options for patients suffering from orphan and non-orphan diseases.

NovelMed Therapeutics, Inc.
11000 Cedar Avenue
Cleveland, Ohio 4106
Tel: (216)707 1775    Email: bd@novelmed.com